Nervous System News and Research

Latest Nervous System News and Research

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.

20 Dec 2010

SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development

SEEK, a leading UK privately-owned drug-discovery group, is pleased to announce the establishment of a new joint venture entity with Pernix Therapeutics Holdings, an integrated specialty pharmaceutical company focused primarily on the United States pediatric market.

20 Dec 2010

Scientists suggest targeting ion channels could offer effective pain relief

University at Buffalo neuroscience researchers conducting basic research on ion channels have demonstrated a process that could have a profound therapeutic impact on pain.

20 Dec 2010

Improved brain-machine technologies

A new study published in the Dec 15 issue of The Journal of Neuroscience found that monkeys were able to move thought-controlled computer cursors more quickly and accurately when provided with additional sensory feedback.

19 Dec 2010

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities:

17 Dec 2010

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease.

17 Dec 2010

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.

17 Dec 2010

Second brain death exam impacts organ donation rates

Requiring a second exam on a person who is considered brain dead may be unnecessary, according to a study on the impact of a second brain death exam on organ donation rates. The research is published in the December 15, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

16 Dec 2010

Adeona expands and enhances zinc-based product candidate portfolio

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration.

16 Dec 2010

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.

16 Dec 2010

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Gedeon Richter Plc today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.

16 Dec 2010

NIH grants $7.5 million for researchers to develop novel compounds in treating nicotine addiction

The Scripps Research Institute and the University of California, San Diego, School of Medicine have been awarded approximately $7.5 million over five years to develop novel compounds that could eventually become drug candidates for the treatment of nicotine dependence, and possibly other drug addictions.

16 Dec 2010

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

Compugen Ltd. announced today that administration of CGEN-15001 in an animal model of rheumatoid arthritis dramatically ameliorates the clinical symptoms of the disease.

15 Dec 2010

Study: HUCBs boost survival and maturation of hippocampal neurons

Laboratory culture studies examining the activity of human umbilical cord blood cells on experimental models of central nervous system aging, injury and disease, have shown that HUCBs provide a 'trophic effect' that enhances survival and maturation of hippocampal neurons harvested from both young and old laboratory animals.

15 Dec 2010

Diamyd Medical issues new shares to cover social security contributions for employee stock option plans

In connection with the exercise of employee stock options in the plans 2007/2010 and 2008/2011, Diamyd Medical is issuing 155,352 new shares of series B to cover social security contributions for the plans. The shares are issued with support of underlying warrants that covers the company's obligations within the scope of the programs.

14 Dec 2010

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Immunomedics Inc. and UCB today announced the enrollment of the first patient into EMBODY™ 1, one of two pivotal Phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE). Patient enrollment for EMBODY™ 2 has also begun.

14 Dec 2010

Majority of brain tumor patients use alternative therapies

Many people with incurable brain tumors use alternative therapies, such as taking vitamins and homeopathy, in addition to their conventional treatments, according to a study published in the December 14, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Dec 2010

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zogenix, Inc. today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System as a 2010 Most Innovative Product (MIP) winner at the MIP Awards Luncheon on December 10, 2010.

13 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

Arena Pharmaceuticals, Inc. announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH.

10 Dec 2010

Nervous System News and Research

Latest Nervous System News and Research

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

SEEK announces new joint venture entity with Pernix Therapeutics for antitussive drug development

Scientists suggest targeting ion channels could offer effective pain relief

Improved brain-machine technologies

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Second brain death exam impacts organ donation rates

Adeona expands and enhances zinc-based product candidate portfolio

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

NIH grants $7.5 million for researchers to develop novel compounds in treating nicotine addiction

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

Study: HUCBs boost survival and maturation of hippocampal neurons

Diamyd Medical issues new shares to cover social security contributions for employee stock option plans

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Majority of brain tumor patients use alternative therapies

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Depression drug appears effective in reducing pain associated with breast cancer treatment

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Nervous System News and Research

Latest Nervous System News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in